Citigroup Inc. (NYSE:C) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.Analysts expect the New York-based company to report quarterly earnings at $1.76 per share, up from $1.51 per share in the year-ago period. Citigroup projects quarterly revenue of $21.12 billion, compared to $20.32 billion a year earlier, according to data from Benzinga Pro.On Sept. 24, Citigroup announced $2.75 billion redemption of 5.610% Fixed Rate/Floating Rate Notes due 2026.Shares o ...

Core Insights - PepsiCo is set to announce its Q3 earnings results on October 9th, before market opening [1] - Wall Street anticipates an EPS of $2.26 for the company [1] - Revenue is projected to increase by 2% to $23.84 billion [1] Financial Expectations - Expected EPS: $2.26 [1] - Expected revenue: $23.84 billion, reflecting a 2% increase [1]

Core Insights - Kimberly-Clark Corporation is a multinational company specializing in hygiene and personal care products, with a market capitalization of $39.99 billion and operations in over 175 countries [1] Financial Performance - The company is expected to report a 10.9% year-over-year decline in profit to $1.63 per diluted share for Q3 fiscal 2025 [2] - For the fiscal year 2025, analysts predict an 11% decrease in profit to $6.50 per diluted share compared to the previous year [3] Stock Performance - Kimberly-Clark's stock has underperformed the broader market, losing 13.1% over the past 52 weeks and 6.7% year-to-date, while the S&P 500 Index has gained 17.9% and 14.2% respectively [4] - The company has also underperformed the Consumer Staples Select Sector SPDR Fund (XLP), which has dropped 3.1% over the past 52 weeks [5] Recent Results - In Q2, Kimberly-Clark reported net sales of $4.16 billion, a 1.6% year-over-year decrease, impacted by a 4.4% adverse effect from divestitures and business exits [6] - The adjusted EPS for Q2 was $1.92, down 2% year-over-year but exceeding analyst expectations of $1.68, leading to a 4.8% intraday stock rise on the reporting day [6]

New York-based KKR & Co. Inc. (KKR) is a private equity and real estate investment firm with a market cap of $111.1 billion. The company specializes in acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, turnaround, lower middle market, and middle market investments. It is scheduled to announce its fiscal Q3 earnings for 2025 before the market opens on Friday, Nov. 7. Before this event, analysts expect this private equity giant to r ...

Core Insights - The Procter & Gamble Company (PG) is set to announce its fiscal Q1 earnings for 2026 on October 24, with a market cap of $357 billion and a diverse portfolio of well-known consumer goods brands [1] Financial Performance - Analysts predict PG will report a profit of $1.90 per share for fiscal Q1 2026, a decrease of 1.6% from $1.93 per share in the same quarter last year [2] - For fiscal 2026, PG is expected to achieve a profit of $6.99 per share, reflecting a 2.3% increase from $6.83 per share in fiscal 2025, with further growth anticipated to $7.42 per share in fiscal 2027 [3] Recent Stock Performance - Over the past 52 weeks, PG's stock has declined by 9.2%, underperforming the S&P 500 Index, which returned 17.9%, and the Consumer Staples Select Sector SPDR Fund, which saw a 3.4% decrease [4] - In its Q4 results reported on July 29, PG's net sales rose by 1.7% year-over-year to $20.9 billion, slightly exceeding consensus estimates, while net earnings increased by 15.3% to $3.6 billion [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for PG, with 11 analysts recommending "Strong Buy," 3 suggesting "Moderate Buy," and 11 advising "Hold," indicating a mean price target of $171, which suggests a potential upside of 12.1% from current levels [6]

Core Insights - ResMed Inc. is set to announce its fiscal Q1 earnings for 2026, with a current market cap of $41.1 billion [1] Financial Performance - Analysts anticipate a profit of $2.49 per share for the upcoming quarter, reflecting a 13.2% increase from $2.20 per share in the same quarter last year [2] - For fiscal 2026, expected profit is projected at $10.80 per share, a 13.1% rise from $9.55 per share in fiscal 2025, with further growth to $11.64 per share in fiscal 2027 [3] Stock Performance - ResMed's shares have increased by 20.3% over the past 52 weeks, outperforming the S&P 500 Index's 17.2% gain and the Health Care Select Sector SPDR Fund's 5% decline [4] Recent Developments - The company reported better-than-expected Q4 results, with revenue growing 10.2% year-over-year to $1.3 billion, exceeding consensus expectations by 2.3% [5] - Adjusted EPS for Q4 was $2.55, a 22.6% increase from the previous year, surpassing analyst estimates by 3.7% [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for ResMed, with 17 analysts providing coverage: 8 recommend "Strong Buy," 2 suggest "Moderate Buy," 6 indicate "Hold," and 1 advises "Strong Sell" [6] - The mean price target for ResMed is $290.92, indicating a potential upside of 3.4% from current levels [6]

Core Insights - Constellation Brands reported revenue of $2.48 billion for the quarter ended August 2025, a decrease of 15% year-over-year, with EPS at $3.63 compared to $4.32 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $2.46 billion by 0.98%, while the EPS surpassed the consensus estimate of $3.37 by 7.72% [1] Revenue and Earnings Performance - Net Sales for Wine and Spirits were reported at $136 million, below the five-analyst average estimate of $138.99 million, reflecting a significant year-over-year decline of 65% [4] - Net Sales for Beer reached $2.35 billion, slightly above the $2.33 billion average estimate, but still represented a year-over-year decrease of 7.3% [4] - Operating Income for Wine and Spirits was reported at -$19.8 million, worse than the estimated -$9.36 million [4] - Operating Income for Beer was $951.6 million, exceeding the average estimate of $911.22 million [4] - Corporate Operations and Other reported an Operating Income of -$45.6 million, better than the estimated -$53.47 million [4] Stock Performance - Shares of Constellation Brands have returned -4.2% over the past month, contrasting with the Zacks S&P 500 composite's increase of 4.3% [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - McCormick & Company, Incorporated (MKC) is expected to report a revenue increase of 2.1% year-over-year, with third-quarter 2025 revenues estimated at $1.71 billion [1][9] - Earnings per share are projected to decline by 2.4% to 81 cents compared to the previous year [2][9] - The company has a trailing four-quarter earnings surprise average of 6.5% [2] Consumer Segment Performance - McCormick is benefiting from strong consumer demand in its core categories, including spices, seasonings, sauces, and condiments [3] - The Consumer segment's momentum is driven by innovation, increased brand marketing investments, and expanded distribution [3] - Health-conscious and flavor-driven cooking trends are resonating with consumers, leading to more home meal preparations [3] Flavor Solutions Segment Challenges - The Flavor Solutions segment is experiencing softness due to sluggish volumes among large consumer packaged goods (CPG) customers [4] - Demand in certain quick-service restaurant (QSR) channels, particularly in the EMEA region, has been muted due to geopolitical tensions and reduced consumer footfall [4] Consumer Behavior Trends - Consumer behavior in major markets like North America is mixed, with value-seeking tendencies leading to smaller purchases [5] - McCormick's strong brand equity and diversified portfolio have helped maintain resilience, but cautious spending patterns may limit pricing power and pressure margins [5] Cost and Inflation Pressures - The company is navigating elevated commodity costs and tariff-related expenses, which have not been fully offset by mitigation efforts [6] - Challenges from volatile foreign currency movements and inflationary impacts on the cost of goods sold remain a concern for the quarter [6] Earnings Prediction Insights - Current models do not predict an earnings beat for McCormick, with a Zacks Rank of 4 (Sell) and an Earnings ESP of -1.70% [7]

Core Insights - Edwards Lifesciences Corporation (EW) is valued at a market cap of $45.2 billion and specializes in products for advanced cardiovascular diseases, particularly known for its SAPIEN transcatheter aortic valve replacement products [1] - The company is set to announce its fiscal Q3 earnings for 2025 on October 30, 2023, with analysts expecting a profit of $0.59 per share, a decrease of 11.9% from the previous year [2] Financial Performance - For fiscal 2025, analysts project EW to report a profit of $2.50 per share, reflecting a 2.9% increase from $2.43 per share in fiscal 2024, with further growth expected to $2.78 per share in fiscal 2026, an 11.2% year-over-year increase [3] - In Q2, EW reported an 11.9% year-over-year revenue increase to $1.5 billion, surpassing consensus estimates by 2.7%, and an adjusted EPS of $0.67, which was 8.1% higher than the previous year [5] Stock Performance - EW's shares have increased by 17.9% over the past 52 weeks, outperforming the S&P 500 Index's 17.8% rise and the Health Care Select Sector SPDR Fund's 4.4% decline during the same period [4] - Following the release of better-than-expected Q2 results, EW's shares surged by 5.5% in the subsequent trading session [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for EW, with 15 out of 31 analysts recommending "Strong Buy," one suggesting "Moderate Buy," 14 advising "Hold," and one indicating "Strong Sell" [6] - The mean price target for EW is set at $86.83, suggesting a potential upside of 12.7% from current levels [6]

PepsiCo, Inc. (NASDAQ:PEP) will release earnings results for the third quarter, before the opening bell on Thursday, Oct. 9.Analysts expect the Purchase, New York-based company to report quarterly earnings at $2.26 per share, down from $2.31 per share in the year-ago period. PepsiCo projects quarterly revenue of $23.86 billion, compared to $23.32 billion a year earlier, according to data from Benzinga Pro.Last month, activist investor Elliott Investment Management took a roughly $4 billion stake in PepsiCo, ...